In the same treatments with NSC373981, two of the three cell lines with decreased CARD11 mRNA (RIVA and HT) display a 25–30% decrease in KRAS or a 40–55% in TERT whereas the other DLBCL cell (HBL1) did not have detectable differences in either KRAS or TERT mRNA (Figure 2D). Here, KRAS is linked to diffuse large B-cell lymphoma.